Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of liposomal doxorubicin and trastuzumab in treating women who have advanced breast cancer.

Key facts

Study ID

NCT00006825

Run by

NYU Langone Health

Starts

2000-07-01

Last updated by the study team

2011-03-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.